Dr. Young on Eltrombopag Added to Immunosuppression for Patients With Aplastic Anemia

Exciting new immunosuppressive therapy treatment for aplastic anaemiaПодробнее

Dr. Neal Young on the Evolving Treatment for Patients Diagnosed With Aplastic AnemiaПодробнее

Frontline Shift for Severe Aplastic Anemia After Eltrombopag FDA ApprovalПодробнее

Relapse Prevention in Aplastic AnemiaПодробнее

Late-Breaking Abstract: Eltrombopag Improves Response in Severe Aplastic AnemiaПодробнее

Conversations with Innovators: Neal Young, MDПодробнее

Eltrombopag increases hematologic response in patients with treatment-naïve severe aplastic anemiaПодробнее

Dr. Deol on the FDA Approval of Eltrombopag in Severe Aplastic AnemiaПодробнее

RACE: evaluating eltrombopag in severe aplastic anemiaПодробнее

Upcoming SAA research: cyclosporine and eltrombopagПодробнее

ASH 2013: Update On Improving Care for Aplastic Anemia PatientsПодробнее

Unrelated transplantation vs. immunosuppression for SAAПодробнее

Aplastic anaemia: immunosuppressant treatment or haploidentical transplant?Подробнее

ASH 2016: Aplastic Anemia Research UpdateПодробнее

Advances in transplantation and drug treatments for idiopathic aplastic anemiaПодробнее

Eltrombopag is a thrombopoietin agonist and has been used in aplastic anemia and post-transplantatioПодробнее

Cutting Edge Approaches to Aplastic Anemia TreatmentПодробнее

Eltrombopag for aplastic anaemia in EuropeПодробнее

Danielle M. TownsleyПодробнее